JPMorgan raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $48 from $45 and keeps a Neutral rating on the shares. The firm updated the company’s model to reflect higher Amvuttra estimates.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals doses first patient in REVEAL study
- Ionis Pharmaceuticals Holds Annual Stockholders Meeting
- Ionis Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Trial Results and Future Prospects
- Cautious Optimism for Ionis Pharmaceuticals Amid Promising Olezarsen Data and Awaited CORE/CORE2 Insights
- Promising Phase 3 Results and Future Prospects of Tryngolza Drive Buy Rating for Ionis Pharmaceuticals